Short 🧵on symptom measurement in #LongCovid / #MECFS and other chronic illnesses. We need to do better. Many of the symptoms that we're trying to track don't have a physical biomarker, and while patient-reported outcomes (PROs) are helpful, then need to be far more (1/n)
On May 17 @theNASEM will publish a new report on Improving Representation in Clinical Trials & Research: Building #ResearchEquity for Women & Underrepresented Groups. Register for the release webinar: https://t.co/v5epkdaHKn #EquityinClinicalTrials
Yes! “ Empowered patients will show up differently “❗️ That is true! @pfizer VP of Global Patient Advocacy 🌍 Emma Andrews gives valuable insight #PatientsasPartners2022
“The experts in the room are #patients. And the experts in the community are its trusted leaders.” Powerful words that speak to the need to communicate and build relationships to ensure diversity, equity, and inclusion in #clinicaltrials#PatientsasPartners2022
Addison Freeman from Reverba: Sponsors can reduce the burden on patients and investigators by engaging and educating patient communities before a study launches. #PatientsasPartners2022
This #GivingTuesday you can help us help patients advocate for research that meets their needs. And if you donate on Facebook, your donation could go twice as far with matching funds! https://t.co/ziX9FJlAnD
ICYMI: Patients' Academy CEO @BiotechSusan recently spoke with eyeforpharma on why patient education is key to scaling engagement and increasing participation in research.
https://t.co/jZBXvvoGk3
Got a minute or two? Join us for our NYC Neuromodulation virtual session about patient engagement practices in neuromodulation development.
April 22 from 3-4PM EDT.
Featuring: @Cara Altimus @Blythe Karow @Yagna Pathak @Susan Schaeffer
Register here: https://t.co/pkmTN1z6FE
ICYMI: Why drug companies should invest in education and training that increases patients' capacity to partner in R&D, by our CEO and @BrendatweetsDC & @tunis_rachel from @fastercures https://t.co/6oCIUuwqR0
Metani Rooms from CSL: when we asked patients what we could do better, feedback touched everything from manufacturing to commercial ops and biostatisticians